chartexchange

5 Pharma Stocks With Net Profit Growth of Up to 156% in Q2 to Keep on Your Radar

Trade Brains | Nov 2, 2026 6:26 AM EST

The Indian pharmaceutical industry remains a strong player in the global healthcare industry, with exports crossing the level of Rs. 2.73 lakh crore (USD 31 billion) in FY26, from Rs. 2.59 lakh crore in FY25. Drug formulations and biologicals made up 74.2% of all export items, which clearly indicates India's growing expertise in medicine supply worldwide.
India exports pharmaceutical products to more than 200 nations, including tightly regulated nations like the USA, Western Europe, Japan, and Australia. India ranks 12th on the list of exporters of medical supplies worldwide and supplies 20% of all generic medicines exported worldwide, positioning itself as one of the biggest exporters of affordable medicines worldwide.

Also Read: Sensex & Nifty 50 | Stock Market Live Updates Today: Sensex, Nifty Close Over 1.6% Higher; Energy, Infra and Metal Stocks Lead Rally

Moreover, the future looks promising for the industry in view of growing international demand for generic medicines, vaccines, and modern healthcare items. As per CII, exports of India's medical technology will cross the mark of USD 20 billion by FY30.
Mankind Pharma Ltd
Mankind Pharma is one of the top pharmaceutical companies in India that manufactures and markets medicines in acute and chronic segments. Some of its products include anti-infective, cardiovascular, gastrointestinal, and anti-diabetic medicines. 
With a market capitalisation of Rs. 1,02,267 cr, the shares of Mankind Pharma Ltd closed at Rs. 2475.95 per share, down from its previous close of Rs. 2488.75 per share. 
On the financial front, Mankind Pharma Ltd reported a strong performance in Q2FY27. Revenue increased 17% YoY to Rs. 4,338 crore from Rs. 3,697 crore in Q2FY26, while EBITDA rose 27% to Rs. 1,171 crore from Rs. 921 crore. Net profit grew 39% to Rs. 716 crore from Rs. 520 crore, with EPS increasing 39% to Rs. 17.23 from Rs. 12.39.
Laurus Labs Ltd
Laurus Labs is a pharmaceutical and biotechnology company offering APIs, finished dosage formulations, and CDMO services. Laurus specializes in the manufacture of antiretroviral (ARVs) and oncology products. In addition, the company is venturing into biotechnology and biologics.
With a market capitalisation of Rs. 1,26,811 cr, the shares of Laurus Labs Ltd closed at Rs. 2347 per share, down from its previous close of Rs. 2392 per share. 
On the financial front, Laurus Labs Ltd reported a strong performance in Q2FY27. Revenue increased 33% YoY to Rs. 2,206 crore from Rs. 1,653 crore in Q2FY26, while EBITDA surged 86% to Rs. 750 crore from Rs. 403 crore. Net profit jumped 126% to Rs. 436 crore from Rs. 194 crore, with EPS rising 126% to Rs. 8.17 from Rs. 3.61.
Piramal Pharma Ltd
Piramal Pharma works in segments such as contract development and manufacturing (CDMO), complex hospital generics, and consumer healthcare products. It offers drug development and manufacturing services for multinational pharmaceutical companies. Some of its other products include injectables, inhalation anaesthetics, and over-the-counter healthcare products.

Also Read: RBM Infracon secures ₹354.76 Cr EPC order from Epitome Industries as shares hit upper circuit

With a market capitalisation of Rs. 31,912 cr, the shares of Piramal Pharma Ltd closed at Rs. 239.70 per share, up from its previous close of Rs. 239.05 per share. 
On the financial front, Piramal Pharma Ltd reported a strong performance in Q2FY27. Revenue increased 28% YoY to Rs. 2,617 crore from Rs. 2,044 crore in Q2FY26, while EBITDA surged 120% to Rs. 349 crore from Rs. 159 crore. The company turned profitable, reporting a net profit of Rs. 5.03 crore compared to a loss of Rs. 99.2 crore in the year-ago quarter. EPS improved to Rs. 0.04 from a negative Rs. 0.75.
Morepen Laboratories Ltd
Morepen Laboratories specialises in the production of active pharmaceutical ingredients (APIs), formulations, and diagnostics. The company is well known for its presence in anti-allergy drugs that include Loratadine, Montelukast, and Desloratadine. In addition, the company is involved in home health care and diagnostic equipment.
With a market capitalisation of Rs. 5,920 cr, the shares of Morepen Laboratories Ltd closed at Rs. 108.05 per share, down from its previous close of Rs. 113.70 per share. 
On the financial front, Morepen Laboratories Ltd reported a strong performance in Q2FY27. Revenue surged 81% YoY to Rs. 746 crore from Rs. 412 crore in Q2FY26, while EBITDA jumped 301% to Rs. 123 crore from Rs. 30.7 crore. Net profit increased 117% to Rs. 88.9 crore from Rs. 41 crore, with EPS rising 116% to Rs. 1.62 from Rs. 0.75.
Aarti Pharmalabs Ltd
Aarti Pharmalabs specialises in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The products offered by the company are in areas such as oncology, cardiovascular, and central nervous system disorders.

Also Read: Small Cap Auto Stock With Strong Earnings Growth, New Capacity and Commercial Vehicle Exposure to Keep on Your Radar

With a market capitalisation of Rs. 8,082 cr, the shares of Aarti Pharmalabs Ltd closed at Rs. 891.30  per share, up from its previous close of Rs. 873.65 per share. 
On the financial front, Aarti Pharmalabs Ltd reported a strong performance in Q2FY27. Revenue increased 46% YoY to Rs. 610 crore from Rs. 418 crore in Q2FY26, while EBITDA surged 82% to Rs. 135 crore from Rs. 74.1 crore. Net profit jumped 156% to Rs. 71.5 crore from Rs. 27.9 crore, with EPS rising 156% to Rs. 7.88 from Rs. 3.08.

Read original article